Cargando…
Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as of May 8, 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current...
Autores principales: | Bonam, Srinivasa Reddy, Kaveri, Srini V., Sakuntabhai, Anavaj, Gilardin, Laurent, Bayry, Jagadeesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190525/ https://www.ncbi.nlm.nih.gov/pubmed/32562483 http://dx.doi.org/10.1016/j.xcrm.2020.100016 |
Ejemplares similares
-
SARS-CoV-2 Induces Cytokine Responses in Human Basophils
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2022) -
Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
por: Galeotti, Caroline, et al.
Publicado: (2020) -
Retrospective analysis on the immunopotentiating mechanism of an emulsion-based vaccine adjuvant on human antigen presenting cells
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2023) -
Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022) -
Cross-presentation of antigens by dendritic cells: role of autophagy
por: Das, Mrinmoy, et al.
Publicado: (2015)